PMID- 7677231
OWN - NLM
STAT- MEDLINE
DCOM- 19951019
LR  - 20190821
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 50
IP  - 25 Suppl
DP  - 1995
TI  - Monitoring allergen exposure in asthma: new treatment strategies.
PG  - 29-33
AB  - The development of monoclonal antibody-based enzyme-linked immunosorbent assay 
      technology for measuring environmental allergen exposure has provided a benchmark 
      for assessing the role of indoor allergens in causing asthma and other allergic 
      diseases. Epidemiological studies from several parts of the world have shown that 
      immunoglobulin E (IgE)-mediated sensitization to indoor allergens (mite, cat, dog 
      and cockroach) is a risk factor for asthma attacks. A dose-response relationship 
      between allergen exposure and sensitization has been demonstrated for mite 
      allergens, and threshold values for exposure levels leading to sensitization or 
      to exacerbations of symptoms have been defined. Comparative studies on airborne 
      allergen levels have made it possible to determine the properties of aeroallergen 
      particles, their concentration in indoor air, and the relationship to clinical 
      symptoms. Together, these studies provide strong evidence that allergen exposure 
      plays a causal role in the development of bronchial hyperreactivity and of the 
      chronic inflammatory responses seen in patients with asthma. Logically, the 
      primary preventive treatment should be allergen avoidance. Through knowledge of 
      indoor allergen levels, both in dust and in the air, different avoidance 
      strategies have been applied to the various indoor allergens, and there is 
      increasing evidence of their clinical efficacy. Monitoring allergen levels in 
      patients' houses should improve their understanding of the role of allergens in 
      asthma and improve compliance with avoidance measures.
FAU - Chapman, M D
AU  - Chapman MD
AD  - Department of Medicine, University of Virginia, Charlottesville 22908, USA.
FAU - Heymann, P W
AU  - Heymann PW
FAU - Sporik, R B
AU  - Sporik RB
FAU - Platts-Mills, T A
AU  - Platts-Mills TA
LA  - eng
GR  - AI 20565/AI/NIAID NIH HHS/United States
GR  - AI 32557/AI/NIAID NIH HHS/United States
GR  - AI 34607/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Allergens)
SB  - IM
MH  - Allergens/analysis
MH  - Asthma/epidemiology/immunology/*therapy
MH  - *Environmental Monitoring
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Epidemiological Monitoring
MH  - Humans
MH  - Prevalence
MH  - Risk Factors
RF  - 33
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.1111/j.1398-9995.1995.tb04273.x [doi]
PST - ppublish
SO  - Allergy. 1995;50(25 Suppl):29-33. doi: 10.1111/j.1398-9995.1995.tb04273.x.